SARS-CoV-2 and the pancreas: What do we know about acute pancreatitis in COVID-19 positive patients?

Giuseppe Brisinda, Maria Michela Chiarello, Giuseppe Tropeano, Gaia Altieri, Caterina Puccioni, Pietro Fransvea, Valentina Bianchi

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause pancreatic damage, both directly to the pancreas via angiotensin-converting enzyme 2 receptors (the transmembrane proteins required for SARS-CoV-2 entry, which are highly expressed by pancreatic cells) and indirectly through locoregional vasculitis and thrombosis. Despite that, there is no clear evidence that SARS-CoV-2 is an etiologic agent of acute pancreatitis. Acute pancreatitis in coronavirus disease 2019 (COVID-19) positive patients often recognizes biliary or alcoholic etiology. The prevalence of acute pancreatitis in COVID-19 positive patients is not exactly known. However, COVID-19 positive patients with acute pancreatitis have a higher mortality and an increased risk of intensive care unit admission and necrosis compared to COVID-19 negative patients. Acute respiratory distress syndrome is the most frequent cause of death in COVID-19 positive patients and concomitant acute pancreatitis. In this article, we reported recent evidence on the correlation between COVID-19 infection and acute pancreatitis.

Key Words: Acute pancreatitis; SARS-CoV-2; Severe acute pancreatitis; Multiparametric scores; Infected necrosis; Step-up approach
Core Tip: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing a severe acute respiratory syndrome, has rapidly spread from China all over the world, affecting millions of people. Whereas typical presentations of this infection (such as fever, cough, myalgia, fatigue and pneumonia) are well recognized, several studies report a low incidence of gastrointestinal symptoms. The relationship between SARS-CoV-2 infection and acute pancreatitis is controversial. Acute pancreatitis is not specifically caused by SARS-CoV-2. Furthermore, coronavirus disease 2019 positive patients are more likely to develop severe acute pancreatitis and multiple organ failure.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) secondary to coronavirus disease 2019 (COVID-19) has spread rapidly from China. The disease has affected millions of people[1]. Whereas typical presentations of this infection (such as fever, cough, myalgia, fatigue and pneumonia) are well recognized, few studies reported the incidence of atypical gastrointestinal symptoms[2-5]. COVID-19 is linked to organ damage including lungs, heart and kidneys and can lead to multiple organ failure. Evidence shows that SARS-CoV-2 has a strong tropism for the gastrointestinal tract[6,7]. Moreover, pancreatic injury in COVID-19 has not been common.

Acute pancreatitis is an inflammatory process that originates from the glandular parenchyma, causing damage and/or destruction to the acinar component first and then extending to the surrounding tissues[8-11]. There are several etiological factors contributing to its onset. However, it is possible to ascribe most of the episodes to two main causes, namely gallbladder lithiasis and alcohol abuse. Pharmacological, iatrogenic and viral causes must also be taken into account[12].

The severity of acute pancreatitis does not always correlate with pancreatic structural changes. It is possible to distinguish interstitial pancreatitis when the organ is locally or wholly increased in volume due to the presence of interstitial edema and necrotizing pancreatitis (10%-20% of all cases)[10,13,14]. It is unclear why COVID-19 starts with exclusively gastrointestinal symptoms, albeit in a low percentage of cases. However, acute pancreatic involvement induced by COVID-19 is severe and can develop rapidly. Close monitoring and admission are necessary to offer proper treatment. The following sections of this editorial discuss some of the recent findings and the approaches for a more effective clinical diagnosis and treatment of acute pancreatitis in patients with SARS-CoV-2 infection.

COVID-19 AND THE PANCREAS

Viral RNA has been found in the stools of COVID-19 patients[1,2,15-17]. High replication of the virus has been documented in both the small and large intestines by electron microscopy studies on tissues derived from biopsies and/or autopsy material[7,18,19]. Additionally, fecal-oral transmission has been documented for SARS-CoV-2[20]. Some molecules are receptors for the virus. These determine a specific tropism for different tissues and organs. SARS-CoV-2 uses its surface envelope called the spike glycoprotein. By means of this protein, SARS-CoV-2 interacts and enters host cells. The virus enters the cell via the angiotensin-converting enzyme 2 (ACE2) receptor. As such, the spike glycoprotein-ACE2 binding is the determinant for virus entry and propagation and for the transmissibility of COVID-19-related disease. ACE2 is expressed in human pancreatic cells and pancreatic islets and highly represented in pancreas microvasculature pericytes[6,21,22]. As ACE2 is internalized by SARS-CoV-2 binding, an imbalance of the RAS peptides can be established with a rise of angiotensin II and a decrease in angiotensin 1-7. The latter exerts anti-thrombogenic, anti-inflammatory and pro-resolving actions[23]. Laboratory abnormalities, suggesting pancreatic injury, have been noted in 8.0%-17.5% of cases in several studies[24,25], with 7.0% displaying significant pancreatic changes on computed tomography.

The etiopathogenesis of pancreatic injury in SARS-CoV-2 patients is still unclear. Both pancreatic ACE2 expression and drugs taken before the hospitalization might be involved[26]. The inflammation that occurs in the intestine causes the release of cytokines and bacteria. Both cytokines and bacteria can
reach and enter the lung through the bloodstream. At this level, a direct influence on the immune response and inflammation is observed[27-29]. The gut-liver axis is also strongly influenced by damage to the intestinal mucosa and bacterial imbalance[30]. The host and the microbial metabolites present in the intestine are transferred to the liver through the mesenteric-portal circulation; these affect liver function. The liver releases bile acids and bioactive media into the biliary and systemic circulation in order to transport them to the intestine. This could lead to pancreatic function damage in patients and may also explain the abnormality of pancreatic function indicators in COVID-19 patients. It is important not to consider each COVID-19 patient with increased serum amylase level as affected by acute pancreatitis[31]. Elevated levels of pancreatic enzymes may occur during kidney failure or diarrhea in the course of COVID-19[32]. It could be useful to find some criteria that can guide clinical suspicion.

**WHAT DO WE KNOW ABOUT ACUTE PANCREATITIS IN COVID-19 POSITIVE PATIENTS?**

Available literature is not able to determine whether the tissue damage leading to acute pancreatitis occurs as a result of direct SARS-CoV-2 infection or as a result of systemic multiple organ dysfunction with increased levels of amylase and lipase[33,34]. Only a few COVID-19 positive patients also have acute pancreatitis; the association between the two pathologies is infrequent. Only 10% of COVID-19 positive patients show abdominal symptoms exclusively[35]: Usually, these patients have the most severe forms of COVID-19 infections. Furthermore, it has not been demonstrated that an increased incidence of acute pancreatitis occurred during the COVID-19 pandemic period[36]. SARS-CoV-2 cannot be said to be an etiologic agent of acute pancreatitis[33,37]. Acute pancreatitis in COVID-19 positive patients is idiopathic in most cases[37], and there is no sufficient evidence showing that COVID-19 can cause acute pancreatitis or negatively impact its prognosis.

The involvement of the pancreatic gland appears possible, in consideration of the fact that ACE2 receptors are present both on exocrine cells and on pancreatic islets[23]. In addition, the ACE2 receptor is expressed more in the pancreatic tissue than in the lungs. Furthermore, SARS-CoV-2 induces the onset of endothelitis, which results in ischemic damage and that can also occur in the pancreas[38].

In the COVID PAN study, it was documented that acute pancreatitis is more severe in COVID-19 positive patients than in COVID-19 negative patients. In them, the onset of multiple organ failure can be linked to factors other than acute pancreatitis[39]. A greater severity of acute pancreatitis, an increased risk of necrosis, intensive care unit admission, persistent organ failure and the need for mechanical ventilation were observed in COVID-19 positive patients with acute pancreatitis. In this same study, 30-day overall mortality from acute pancreatitis was statistically higher in COVID-19 positive (14.7%) than in COVID-19 negative patients (2.6%, \( P < 0.04 \))[39]. Furthermore, necrosectomy was more likely to be performed in SARS-CoV-2 positive patients, occurring in 5% compared with 1.3% in the control group (\( P < 0.001 \)).

The predominant organ dysfunction was respiratory failure in the majority of COVID-19 positive patients. In addition, acute pancreatitis with concomitant SARS-CoV-2 was more likely to have poorer outcomes due to double pulmonary damage[40]. Lung involvement is common in severe acute pancreatitis. This involvement can progress to full blown acute respiratory distress syndrome[40]. At present, it could be difficult to stratify the severity of symptoms and the degree of lung involvement. Acute respiratory distress syndrome due to acute pancreatitis can worsen lung injury related to COVID-19 pneumonia. Moreover, changes in the gastrointestinal flora affect the respiratory tract through the common mucosal immune system, the so-called "gut-lung axis"[27,29]. COVID-19 positive patients with gastrointestinal symptoms are more likely to be complicated with acute respiratory distress and pancreatic damage. These patients the prognosis is poorer. In COVID-19 positive patients with gastrointestinal symptoms, attention should be paid to the patient’s gastrointestinal symptoms in the diagnosis and treatment process. It also appears essential to prevent the transmission of the virus via the fecal-oral route. In a retrospective cohort study, Inamdar et al[37] concluded that pancreatitis should be included in the list of gastrointestinal manifestations of COVID-19.

There are few studies in the literature that investigate the relationship between COVID-19 infection and acute pancreatitis. In their experience, Inamdar et al[37] documented 189 cases of acute pancreatitis in 48012 hospitalized patients (0.39%). Thirty-two (17%) of these 189 patients were COVID-19 positive, with a prevalence of 0.27% of acute pancreatitis among the patients hospitalized for COVID-19. Idiopathic forms were more frequent (69%) in this patient group than in COVID-19 negative patients (21%, \( P < 0.0001 \)). Wang et al[41] found that of 52 COVID-19 patients enrolled, 17% had pancreatic injury, defined as an abnormal increase of amylase and lipase serum levels. Stephens et al[31] showed that COVID-19 patients had an amylase serum peak not always related with acute pancreatitis. They enrolled 234 patients, 158 of which had a serum amylase level three times greater than the normal upper limit, but only 1.7% of the studied population met the revised criteria of Atlanta for diagnosis of acute pancreatitis[31].
COVID-19 VACCINE AND PANCREATITIS

Vaccines are considered one of the most important public health achievements of the last century. Many vaccines have side effects. One of these adverse events is the onset of pancreatitis. In these cases, it is believed that acute pancreatitis is secondary to an immunologically induced phenomenon as demonstrated by reports in the literature after the administration of vaccines against the hepatitis virus or other viruses[42-44]. The vaccine BNT162b1 developed by Pfizer-BioNTech is a nucleoside-modified mRNA that encodes the receptor binding domain of the SARS-CoV-2 spike protein. The vaccine RNA is formulated in lipid nanoparticles for an efficient delivery into cells after injections[45].

In the literature there are several cases reporting acute pancreatitis after mRNA-based vaccine[46-50]. Although the vaccine has been proven to be effective and safe, vaccine-induced side effects have been observed. There are nausea, diarrhea, decreased appetite, abdominal pain, vomiting, heartburn and constipation among the most frequently reported gastrointestinal side effects. Most of the cases describe mild acute pancreatitis, however Ozaka et al[46] and Walter et al[47] reported a single case of necrotizing pancreatitis. According to Pfizer’s data, 1 case of pancreatitis and 1 case of obstructive pancreatitis as adverse reactions were observed during the phase II/clinical trial of the COVID-19 mRNA vaccine. The trial included about 38000 participants, indicating that such a link between vaccination and pancreatitis is a very rare adverse event[51]. Between December 9, 2020 and July 21, 2021, information obtained from the United Kingdom database showed 275820 adverse reaction reports, which included 18 cases of mild acute pancreatitis and 1 case of necrotizing pancreatitis[52]. In France, out of a total of 4252357 doses, the Agence Nationale de Sécurité du Medicament et des Produits de Santé reported 57 cases of acute pancreatitis[53]. VigiBase, the World Health Organization global database of individual case safety reports, included 298 cases of acute pancreatitis and 17 cases of necrotizing pancreatitis[54]. The Agenzia Italiana del Farmaco reported 497 gastrointestinal adverse events equal to 14.1% of the total observations in 1 year. The document does not specify the number of cases of acute pancreatitis[55]. Although it is difficult to make conclusions about the likelihood of the vaccine being the etiologic factor of pancreatitis, it is essential to continue monitoring it for possible under-reported side effects until we have extensive long-term data available in post-marketing surveillance for long-term and rare side effects. Surveillance is also necessary because there are currently no conclusive data on the severity of pancreatitis in the population of subjects vaccinated against COVID-19 compared to patients who have not undergone vaccination. Preliminary results would document a reduced incidence of severe forms of acute pancreatitis in subjects vaccinated against SARS-CoV-2.

DO WE NEED TO CHANGE THE DIAGNOSTIC AND THERAPEUTIC APPROACH?

Since pancreatitis in COVID-19 positive patients occurs more frequently in severe forms, treatment must be intensive and prompt. It is crucial to define and stratify the severity of illness in patients with acute pancreatitis because of the extreme range of potential clinical courses due to the wide range of organs and tissues that may become involved. It is also fundamental to identify patients with potentially severe pancreatitis who require a multidisciplinary approach and an earlier and more aggressive treatment[56, 57]. Suspected acute pancreatitis can be confirmed with laboratory and instrumental investigations. Increased pancreatic enzymes levels are associated with a poor prognosis in COVID-19 patients. Recent findings show that the increment of pancreatic enzymes are significant in critical COVID-19 patients, but only a few of them progress to acute pancreatitis[58]. The rapid response of C-reactive protein to
changes in the inflammatory process intensity has also suggested its use in the management and monitoring of acute pancreatitis. C-reactive protein is not specific, and although it is correlated with severity, it cannot be used to predict clinical evolution. Serum procalcitonin is also one of the parameters used in predicting the development of severe acute pancreatitis. Its continuous increase correlates with a bacterial superinfection of pancreatic necrosis. In all patients with or without SARS-CoV-2 illness contrast-enhanced computed tomography scan is the gold standard for the diagnosis of acute pancreatitis to evaluate both pancreatic and extrapancreatic alterations (Figure 1).

The revised Atlanta classification provides a good clinical distinction between mild, moderate and severe acute pancreatitis, and it is used in most COVID-19 positive patients with acute pancreatitis. Several scoring systems have been developed to predict the severity of acute pancreatitis; however, none of them represents a gold standard. The scoring systems are without clinical relevance because of their low predictive value. The bedside index for severity in acute pancreatitis failed to identify the severity of acute pancreatitis in COVID-19 positive patients.

Early fluid resuscitation is recommended in order to improve tissue perfusion, and the maintenance of microcirculation may be associated with resolution of multiple organ failure, especially in patients with COVID-19 and acute pancreatitis. Enteral nutrition is safe during acute pancreatitis. Moreover, supplementation of enteral nutrition with probiotics may decrease septic
Figure 4 Intraoperative photos. A: Surgery was performed for severe abdominal hypertension due to acute pancreatitis with necrotic collections in the retroduodenal region; B: Surgery was performed for severe abdominal hypertension due to acute pancreatitis with necrotic collections along the paracolic gutter.

complications. In patients with COVID-19 requiring mechanical ventilation, early enteral nutrition is associated with earlier liberation from ventilator support, shorter intensive care unit and hospital stay and decreased cost[63,64].

Most patients with sterile necrosis can be managed without invasive treatments. Walled off necrotic collections or pseudocysts may cause mechanical obstruction and a step-up approach is indicated. Percutaneous or transmural endoscopic drainage are both appropriate first-line approaches in managing these patients (Figure 2). However, endoscopic drainage is preferred as it avoids the risk of forming a pancreatocutaneous fistula. In the earlier phase of the pandemic, patients with COVID-19, especially with severe pneumonia and considered highly contagious, did not undergo endoscopic ultrasound or endoscopic treatments. In the later stages, patients with COVID-19 and acute pancreatitis were subjected, with necessary precautions, to percutaneous and endoscopic treatments similar to the COVID-19 negative patients (Figure 3).

The step-up approach might reduce the rates of complications and death by minimizing surgical trauma in already critically ill patients[65,66]. Currently, there is general agreement that surgery in severe acute pancreatitis should be performed as late as possible[67]. In the management of necrotizing acute pancreatitis, open operative debridement (Figure 4) maintains a role in cases not amenable to less invasive endoscopic and/or laparoscopic procedures. Open operative debridement was performed in patients with COVID-19 related lung symptoms and lesions.

CONCLUSION

In pandemic times, clinical conditions could be worsened by COVID-19 infection. SARS-CoV-2 cannot be said to be an etiological agent of acute pancreatitis. Acute pancreatitis in COVID-19 positive patients is idiopathic in most cases, and there is no sufficient evidence showing that SARS-CoV-2 can negatively impact prognosis. On the other hand, acute pancreatitis with concomitant SARS-CoV-2 is more likely to have worse outcomes due to double lung damage and greater pancreatic severity. The multiparametric scores could not recognize and stratify the severity of pancreatic diseases and concomitant COVID-19 infection. In these patients, computed tomography is the gold standard for the diagnosis. Management of COVID-19 positive patients with pancreatitis is complex, and it is optimally provided by a multidisciplinary team. Operative treatments should be modulated, preferably, from the least to the most invasive option. Thus, surgical necrosectomy is relegated to the role of “last resort”, remembering that necrotizing pancreatitis is a heterogeneous disease with marked variations in extent and course. This also means that one size treatment does not fit all.
FOOTNOTES

Author contributions: Brisinda G and Chiarello MM equally contributed to the drafting of the manuscript and must both be considered first author; Chiarello MM and Brisinda G conceived the original idea; Tropeano G, Alteri G, Puccioni C, Fransvea P and Bianchi V performed a comprehensive review of all available literature and summarized the data; Brisinda G and Chiarello MM meet the criteria for authorship established by the International Committee of Medical Journal Editors and verify the validity of the results reported; and all authors read and approved the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Italy

ORCID number: Giuseppe Brisinda 0000-0001-8820-9471; Maria Michela Chiarello 0000-0003-3455-0062; Giuseppe Tropeano 0000-0001-9006-5040; Gaia Altiere 0000-0002-0324-2430; Caterina Puccioni 0000-0001-6092-7957; Pietro Fransvea 0000-0003-4969-3373; Valentina Bianchi 0000-0002-8817-3760.

S-Editor: Wang JJ
L-Editor: Filopodia
P-Editor: Wang JJ

REFERENCES

1 Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu J, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu YJ, Chen Z, Li G, Zheng ZJ, Quj SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002532]

2 Henry BM, de Oliveira MHS, Benoit J, Lippi G. Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis. Intern Emerg Med 2020; 15: 857-859 [PMID: 32303970 DOI: 10.1007/s11739-020-02329-9]

3 Nobel YR, Phipps M, Zucker J, Lembholz B, Wang TC, Sobieszczuk YM, Freedberg DE. Gastrointestinal Symptoms and Coronavirus Disease 2019: A Case-Control Study From the United States. Gastroenterology 2020; 159: 373-375.e2 [PMID: 32294477 DOI: 10.1053/j.gastro.2020.04.017]

4 Nayar M, Varghese C, Kanwar A, Siriwardena AK, Haque AR, Awad A, Balakrishnan A, Rawasdeh A, Ivanov B, Parmar C, Halloran CM, Caruna C, Borg CM, Gomez D, Damaskos D, Karavias D, Finch G, Ebied H, Pine JK, Skipworth JRA, Milburn J, Latif I, Apollis J, El Kafsi J, Windsor JA, Holmes M, Phillips M, Okocha M, Wilson MS, Ameer NA, Kumar N, Shah N, Lapolla P, Magee C, Al-Sarireh B, Lunevicius R, Benhmida R, Singhal R, Balachandran S, Demirli Atici S, Jaunoo S, Dwerryhouse S, Boyce T, Charalampakis V, Kanakala V, Abbas Z, Tewari N, Pandanaboyana S; COVIDPAN Collaborative Group; COVID Pain Collaborative Group. SARS-CoV-2 infection is associated with an increased risk of idiopathic acute pancreatitis but not pancreatic exocrine insufficiency or diabetes: long-term results of the COVIDPAN study. Gut 2022; 71: 1444-1447 [PMID: 34764192 DOI: 10.1136/gutjnl-2021-326218]

5 Troncone E, Salvatori S, Sena G, De Cristofaro E, Affieri N, Marafini I, Paganeli C, Argiro R, Giammaredi D, Monte Leone G, Del Vecchio Bianco G. Low Frequency of Acute Pancreatitis in Hospitalized COVID-19 Patients. Pancreas 2021; 50: 393-398 [PMID: 3385971 DOI: 10.1097/MPA.0000000000001770]

6 Akarsu C, Karabulut M, Aydin H, Sahbaz NA, Dural AC, Yegul D, Peker KD, Feralman S, Bulut S, Dönmez T, Asar S, Yasar KK, Adas GT. Association between Acute Pancreatitis and COVID-19: Could Pancreatitis Be the Missing Piece of the Puzzle about Increased Mortality Rates? J Investig Surg 2022; 35: 119-125 [PMID: 33138653 DOI: 10.1080/08941939.2020.1833263]

7 Cholankeril G, Podboy A, Aivaliotis VL, Pham EA, Spencer SP, Kim D, Ahmed A. Association of Digestive Symptoms and Hospitalization in Patients With SARS-CoV-2 Infection. Am J Gastroenterol 2020; 115: 1129-1132 [PMID: 32618665 DOI: 10.14309/aig.0000000000000712]

8 Banks PA, Bollen TL, Dervenis C, Goossen HG, Johnson CD, Sarr MG, Tsitso GS, Veeg SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-111 [PMID: 23100216 DOI: 10.1136/gutjnl-2012-302779]

9 Seppänen H, Puolakainen P. Classification, Severity Assessment, and Prevention of Recurrences in Acute Pancreatitis. Scand J Surg 2020; 109: 53-58 [PMID: 32192420 DOI: 10.1111/1475-4969.1201007]

10 Leppäniemi A, Tolonen M, Tarasconi A, Segovia-Lohse H, Gamberini E, Kirkpatrick AW, Ball CG, Parry N, Sartelli M, Wolbrink D, van Goor H, Baiocchi G, Ansaloni L, Biffi W, Coccolini F, Di Saverio S, Kluger Y, Moore EE, Catena F. Executive summary: WSES Guidelines for the management of severe acute pancreatitis. J Trauma Acute Care Surg 2020;
Pancreatitis. Inamdar S. DOI: 10.1017/S0950268820001910

COVID-19: results of the UMC-19-Investigators in Emergency Situations TeAm (SIESTA) network. Frequency of five unusual presentations in patients with COVID-19. Mao R. DOI: 10.1111/j.1399-5017.2021.16136.x

Pancreas. Abramczyk U. COVID-19: new classification? Ann Surg 2015; 261: e101-e102. DOI: 10.4240/wjgs.v13.i6.574

Stephens JR. Gastroenterology 2020; 158: 2298-2301.e7. DOI: 10.1053/j.gastro.2020.03.045

Correia de Sá T, Soares C, Rocha M. Acute pancreatitis and COVID-19: A literature review. World J Gastroenterol 2021; 17: 573-584. DOI: 3419462886. DOI: 10.4240/wjgs.v13.i6.574

Rubin R. SARS-CoV-2 RNA Can Persist in Stool Months After Respiratory Tract Cures. Jama 2022; 327: 2175-2176. DOI: 35583898. DOI: 10.1001/jama.2022.7892

Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, Thursz M, Manousou P, Corbett R, Goldin R, Al-Sarraj S, Abdolrasouli A, Swann OC, Baillon L, Penn R, Barclay WS, Viola P, Osborn M. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe 2020; 1: e245-e253. DOI: 52844161. DOI: 10.1016/s2666-5247(20)30115-4

Chmielik E, Jazzowiecka-Rakus J, Dyduck G, Nasierowska-Guttmejer A, Michalowski L, Sochaniak A, Ulatowska-Bialas M. COVID-19 Autopsies: A Case Series from Poland. Pathobiology 2021; 88: 78-87. DOI: 33254171. DOI: 10.1159/000512768

Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology 2020; 158: 1518-1519. DOI: 32142785. DOI: 10.1053/j.gastro.2020.02.054

Dulan R, Bornstein SR, El-Armouche A, Rodionov RN, Markov A, Wielockx B, Beuschlein F, Boehm BO. The ACE-2 in COVID-19: Foe or Friend? Horm Metab Res 2020; 52: 257-263. DOI: 32340044. DOI: 10.1053/j.ajhm.2020.05.003

Shaharuddin SH, Wang Y, Santos RS, Gross A, Wang Y, Jawanda H, Zhang Y, Wasan H, Garcia G Jr, Anumugaswami V, Sareen D. Deleterious Effects of SARS-CoV-2 Infection on Human Pancreatic Cells. Front Cell Infect Microbiol 2021; 11: 678482. DOI: 34282405. DOI: 10.3389/fcimb.2021.678482

Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol 2020; 18: 2128-2130.e2. DOI: 32334082. DOI: 10.1016/j.cgh.2020.04.040

Zhou Z, Zhao N, Shu Y, Han S, Chen B, Shu X. Effect of Gastrointestinal Symptoms in Patients With COVID-19. Gastroenterology 2020; 158: 2294-2297. DOI: 32199880. DOI: 10.1053/j.gastro.2020.03.020

Alosyus MM, Thatti A, Gupta A, Sharma N, Bansal P, Goyal H. COVID-19 presenting as acute pancreatitis. Pancreatology 2020; 20: 1026-1027. DOI: 32344169. DOI: 10.1016/j.pan.2020.05.003

Annunziata A, Coppola A, Andreozzi P, Lanza M, Simioli F, Caramante N, Di Somma C, Di Micco P, Fiorentino G. Acute Pancreatitis and COVID-19: A Single-Center Experience. J Multidiscip Healthc 2021; 14: 2857-2861. DOI: 34675533. DOI: 10.2147/jmdh.s334835

Aktaş B, Aslım B. Gut-lung axis and dysbiosis in COVID-19. Turk J Biol 2020; 44: 265-272. DOI: 32595361. DOI: 10.3906/biy-2005-102

Dang AT, Marsland BJ. Microbes, metabolites, and the gut-lung axis. Mucosal Immunol 2019; 12: 843-850. DOI: 30970087. DOI: 10.1038/s41385-019-0160-6

Marsland BJ, Trompetta A, Gollwitzer ES. The Gut-Lung Axis in Respiratory Disease. Ann Am Thorac Soc 2015; 12 Suppl 2: S150-S156. DOI: 10.1513/AnnalsATS.201503-133AW

Abillos A, de Gottardi A, Reseigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol 2022; 74: 558-577. DOI: 31622696. DOI: 10.1016/j.jhep.2019.10.003

Stephens JR. Wong JLC, Broomhead R, Stümpfle R, Waheed U, Patel P, Brett SJ, Soni S. Raised serum amylase in COVID-19 patients: a case-control study. Br J Surg 2021; 108: e152-e153. DOI: 33793756. DOI: 10.1093/bjs/zaaa168

Abramczyk U, Nowaczyński M, Słomczyński A, Wojnicz P, Zatyka P, Kuzan A. Consequences of COVID-19 for the Pancreas. Int J Mol Sci 2022; 23. DOI: 35055050. DOI: 10.3390/ijms23200864

de-Madaria E, Capurso G. COVID-19 and acute pancreatitis: examining the causality. Nat Rev Gastroenterol Hepatol 2021; 18: 3-4. DOI: 33203968. DOI: 10.1038/s41575-020-00389-y

Suchman K, Raphael KL, Liu Y, Wee D, Trindade AJ. Northwell COVID-19 Research Consortium. Acute pancreatitis in children hospitalized with COVID-19. Pancreatology 2021; 21: 31-33. DOI: 33390915. DOI: 10.1016/j.pan.2020.12.005

Mao R, Qui Y, He JS, Tan JY, Li XH, Liang J, Shen J, Zhu LR, Chen Y, Iacucci M, Ng SC, Ghosh S, Chen MH. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 667-678. DOI: 32405603. DOI: 10.1016/s2468-1253(20)30126-6

Miró Ó, Llorens P, Jiménez S, Piñera P, Burillo-Putze G, Martin A, Martín-Sánchez FJ, Gonzalez Del Castillo J. Spanish Investigators in Emergency Situations TeAm (SIESTA) network. Frequency of five usual presentations in patients with COVID-19: results of the UMC-19-S, Epidemiol Infect 2020; 148: e189. DOI: 32843127. DOI: 10.1017/s0950268820001910

Inamdar S, Benias PC, Liu Y, Sejal DV, Sapathaky SK, Trindade AJ. Northwell COVID-19 Research Consortium. Prevalence, Risk Factors, and Outcomes of Hospitalized Patients With Coronavirus Disease 2019 Presenting as Acute Pancreatitis. Gastroenterology 2020; 159: 2226-2228.e2. DOI: 32860787. DOI: 10.1053/j.gastro.2020.08.044
Rasmussen HH, Van Hooff JE, Bischoff SC. ESPEN guideline on clinical nutrition in acute and chronic pancreatitis. *Clin Nutr* 2020; 39: 612-631 [PMID: 32008871 DOI: 10.1016/j.clnu.2020.01.004]

63 Haines K, Parker V, Ohnuma T, Krishnamoorthy V, Raghunathan K, Sulo S, Kerr KW, Besecker BY, Cassady BA, Wischmeyer PE. Role of Early Enteral Nutrition in Mechanically Ventilated COVID-19 Patients. *Crit Care Explor* 2022; 4: e0683 [PMID: 35464756 DOI: 10.1097/CCE.0000000000000683]

64 Compher C, Bingham AL, McCall M, Patel J, Rice TW, Braunschweig C, McKeever L. Guidelines for the provision of nutrition support therapy in the adult critically ill patient: The American Society for Parenteral and Enteral Nutrition. *JPEN J Parenter Enteral Nutr* 2022; 46: 12-41 [PMID: 34784064 DOI: 10.1002/jpen.2267]

65 Besselink MG, van Santvoort HC, Nieuwenhuis VB, Boermeester MA, Bollen TL, Buskens E, Dejong CH, van Eijck CH, van Goor H, Hofker SS, Lamers JS, van Leeuwen MS, Ploeg RJ, van Ramshorst B, Schaapherder AF, Cuesta MA, Consten EC, Gouma DJ, van der Harst E, Hesselink EJ, Houdijk LP, Karsten TM, van Laarhoven CJ, Pierie JP, Rosman C, Bilgen EJ, Timmer R, van der Tweel I, de Wit RJ, Witteman BJ, Gooszen HG; Dutch Acute Pancreatitis Study Group. Minimally invasive ‘step-up approach’ vs maximal necrosectomy in patients with acute necrotising pancreatitis (PANTER trial): design and rationale of a randomised controlled multicenter trial [ISRCTN13975868]. *BMJ Surg* 2006; 6: 6 [PMID: 16606471 DOI: 10.1186/1471-2482-6-6]

66 Hollemans RA, Bakker OJ, Boermeester MA, Bollen TL, Bosscha K, Bruno MJ, Buskens E, Dejong CH, van Duijvendijk P, van Eijck CH, Fockens P, van Goor H, van Grevenstein WM, van der Harst E, Heisterkamp J, Hesselink EJ, Hofker S, Houdijk AP, Karsten T, Kruyt PM, van Laarhoven CJ, Laméris JS, van Leeuwen MS, Manusama ER, Molenaar IQ, Nieuwenhuis VB, van Ramshorst B, Roos D, Rosman C, Schaapherder AF, van der Schelling GP, Timmer R, Verdonk RC, de Wit RJ, Gooszen HG, Besselink MG, van Santvoort HC; Dutch Pancreatitis Study Group. Superiority of Step-up Approach vs Open Necrosectomy in Long-term Follow-up of Patients With Necrotizing Pancreatitis. *Gastroenterology* 2019; 156: 1016-1026 [PMID: 30391468 DOI: 10.1053/j.gastro.2018.10.045]

67 Boxhoorn L, van Dijk SM, van Grinsven J, Verdonk RC, Boermeester MA, Bollen TL, Bouwense SAW, Bruno MJ, Cappendijk VC, Dejong CH, Duijvendijk P, van Eijck CHJ, Fockens P, Francken MFG, van Goor H, Hadithi M, Hallensleben ND, Haveman JW, Jacobs MAJM, Jansen JM, Kop MPM, van Lienden KP, Manusama ER, Mieog JSD, Molenaar IQ, Nieuwenhuis VB, Poen AC, Poley JW, van de Poll M, Quispel R, Römkens TEH, Schwartz MP, Seerden TC, Stommel MWJ, Straathof JWA, Timmerhuis HC, Vennuman NG, Voermans RP, van de Vrie W, Witteman BJ, Dijkgraaf MGW, van Santvoort HC, Besselink MG; Dutch Pancreatitis Study Group. Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis. *N Engl J Med* 2021; 385: 1372-1381 [PMID: 34614330 DOI: 10.1056/NEJMoa2100826]
